CASSAVA SCIENCES INC (SAVA) Stock Fundamental Analysis

NASDAQ:SAVA • US14817C1071

2.13 USD
-0.04 (-1.84%)
At close: Feb 20, 2026
2.12 USD
-0.01 (-0.47%)
After Hours: 2/20/2026, 8:04:16 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

2

Overall SAVA gets a fundamental rating of 2 out of 10. We evaluated SAVA against 191 industry peers in the Pharmaceuticals industry. SAVA scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. SAVA does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

0

1. Profitability

1.1 Basic Checks

  • In the past year SAVA has reported negative net income.
  • SAVA had a negative operating cash flow in the past year.
  • SAVA had negative earnings in each of the past 5 years.
  • In the past 5 years SAVA always reported negative operating cash flow.
SAVA Yearly Net Income VS EBIT VS OCF VS FCFSAVA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 -50M -100M

1.2 Ratios

  • Looking at the Return On Assets, with a value of -81.73%, SAVA is doing worse than 75.39% of the companies in the same industry.
  • SAVA has a worse Return On Equity (-129.99%) than 67.54% of its industry peers.
Industry RankSector Rank
ROA -81.73%
ROE -129.99%
ROIC N/A
ROA(3y)-37.34%
ROA(5y)-26.18%
ROE(3y)-40.31%
ROE(5y)-28.11%
ROIC(3y)N/A
ROIC(5y)N/A
SAVA Yearly ROA, ROE, ROICSAVA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 -20 -40 -60 -80 -100

1.3 Margins

  • SAVA does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
SAVA Yearly Profit, Operating, Gross MarginsSAVA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

6

2. Health

2.1 Basic Checks

  • The number of shares outstanding for SAVA has been increased compared to 1 year ago.
  • SAVA has more shares outstanding than it did 5 years ago.
  • SAVA has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
SAVA Yearly Shares OutstandingSAVA Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M
SAVA Yearly Total Debt VS Total AssetsSAVA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M 250M

2.2 Solvency

  • SAVA has an Altman-Z score of -6.18. This is a bad value and indicates that SAVA is not financially healthy and even has some risk of bankruptcy.
  • SAVA has a worse Altman-Z score (-6.18) than 65.44% of its industry peers.
  • SAVA has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -6.18
ROIC/WACCN/A
WACCN/A
SAVA Yearly LT Debt VS Equity VS FCFSAVA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100M -100M 200M

2.3 Liquidity

  • A Current Ratio of 2.27 indicates that SAVA has no problem at all paying its short term obligations.
  • With a Current ratio value of 2.27, SAVA perfoms like the industry average, outperforming 42.41% of the companies in the same industry.
  • SAVA has a Quick Ratio of 2.27. This indicates that SAVA is financially healthy and has no problem in meeting its short term obligations.
  • SAVA has a Quick ratio of 2.27. This is comparable to the rest of the industry: SAVA outperforms 47.64% of its industry peers.
Industry RankSector Rank
Current Ratio 2.27
Quick Ratio 2.27
SAVA Yearly Current Assets VS Current LiabilitesSAVA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

1

3. Growth

3.1 Past

  • The Earnings Per Share has grown by an impressive 37.50% over the past year.
EPS 1Y (TTM)37.5%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%62.07%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • Based on estimates for the next years, SAVA will show a very strong growth in Earnings Per Share. The EPS will grow by 102.72% on average per year.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-35.77%
EPS Next 2Y6.85%
EPS Next 3Y102.72%
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
SAVA Yearly Revenue VS EstimatesSAVA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2017 200K 400K 600K 800K 1M
SAVA Yearly EPS VS EstimatesSAVA Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2019 2020 2021 2022 2023 2024 2025 2026 2027 0 2 -2 4 6 8

More info and screens

Find the best growth stocksShow best growing peers

1

4. Valuation

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for SAVA. In the last year negative earnings were reported.
  • Also next year SAVA is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
SAVA Price Earnings VS Forward Price EarningsSAVA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
SAVA Per share dataSAVA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1

4.3 Compensation for Growth

  • SAVA's earnings are expected to grow with 102.72% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y6.85%
EPS Next 3Y102.72%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • No dividends for SAVA!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

CASSAVA SCIENCES INC

NASDAQ:SAVA (2/20/2026, 8:04:16 PM)

After market: 2.12 -0.01 (-0.47%)

2.13

-0.04 (-1.84%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)11-12
Earnings (Next)03-03
Inst Owners28.67%
Inst Owner Change-4.23%
Ins Owners5.77%
Ins Owner Change1.23%
Market Cap102.90M
Revenue(TTM)N/A
Net Income(TTM)-106.03M
Analysts82.86
Price Target5.1 (139.44%)
Short Float %16.84%
Short Ratio8.26
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-11.11%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 1.26
P/tB 1.26
EV/EBITDA N/A
EPS(TTM)-1.45
EYN/A
EPS(NY)-1.24
Fwd EYN/A
FCF(TTM)-1.74
FCFYN/A
OCF(TTM)-1.73
OCFYN/A
SpS0
BVpS1.69
TBVpS1.69
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -81.73%
ROE -129.99%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-37.34%
ROA(5y)-26.18%
ROE(3y)-40.31%
ROE(5y)-28.11%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 16.53%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.27
Quick Ratio 2.27
Altman-Z -6.18
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)81.28%
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)37.5%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%62.07%
EPS Next Y-35.77%
EPS Next 2Y6.85%
EPS Next 3Y102.72%
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y17.38%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-3.46%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-3.42%
OCF growth 3YN/A
OCF growth 5YN/A

CASSAVA SCIENCES INC / SAVA FAQ

What is the ChartMill fundamental rating of CASSAVA SCIENCES INC (SAVA) stock?

ChartMill assigns a fundamental rating of 2 / 10 to SAVA.


What is the valuation status of CASSAVA SCIENCES INC (SAVA) stock?

ChartMill assigns a valuation rating of 1 / 10 to CASSAVA SCIENCES INC (SAVA). This can be considered as Overvalued.


What is the profitability of SAVA stock?

CASSAVA SCIENCES INC (SAVA) has a profitability rating of 0 / 10.


What is the earnings growth outlook for CASSAVA SCIENCES INC?

The Earnings per Share (EPS) of CASSAVA SCIENCES INC (SAVA) is expected to decline by -35.77% in the next year.